Profile data is unavailable for this security.
About the company
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
- Revenue in USD (TTM)22.28bn
- Net income in USD2.91bn
- Incorporated1995
- Employees62.35k
- LocationMerck KGaAFrankfurter Str. 250DARMSTADT 64293GermanyDEU
- Phone+49 6151720
- Fax+49 6 151722000
- Websitehttps://www.emdgroup.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moderna Inc | 5.15bn | -5.97bn | 53.67bn | 5.60k | -- | 4.18 | -- | 10.41 | -15.66 | -15.66 | 13.51 | 33.46 | 0.2523 | 7.78 | 8.24 | 920,178.60 | -29.22 | 20.95 | -34.13 | 29.51 | 22.43 | -- | -115.82 | 32.10 | 3.91 | -- | 0.0429 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| Zoetis Inc | 8.73bn | 2.39bn | 77.82bn | 14.10k | 32.87 | 15.41 | 26.97 | 8.91 | 5.19 | 5.19 | 18.95 | 11.07 | 0.6216 | 1.00 | 7.05 | 619,432.60 | 17.00 | 14.47 | 19.66 | 17.18 | 70.13 | 69.80 | 27.34 | 25.77 | 1.94 | 16.82 | 0.5659 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Merck KGaA (ADR) | 22.28bn | 2.91bn | 80.28bn | 62.35k | 27.39 | 2.67 | 16.59 | 3.60 | 1.34 | 1.34 | 10.25 | 13.78 | 0.4243 | 1.82 | 4.81 | 354,126.40 | 5.57 | 5.64 | 6.96 | 7.27 | 58.03 | 61.86 | 13.13 | 12.97 | 0.8157 | 29.56 | 0.261 | 9.26 | -5.57 | 7.19 | -15.09 | 21.40 | 14.77 | -- |
| Gilead Sciences, Inc. | 27.45bn | 484.00m | 81.06bn | 18.00k | 180.93 | 4.62 | 25.31 | 2.95 | 0.3596 | 0.3596 | 21.89 | 14.08 | 0.4646 | 3.88 | 6.22 | 1,525,000.00 | 0.7718 | 6.74 | 0.9624 | 8.12 | 75.78 | 78.64 | 1.66 | 16.95 | 0.9365 | 13.67 | 0.5907 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Bristol-Myers Squibb Co | 45.53bn | -6.15bn | 83.52bn | 34.10k | -- | 5.06 | 22.40 | 1.83 | -3.10 | -3.10 | 22.15 | 8.14 | 0.4711 | 3.92 | 5.18 | 1,335,308.00 | -6.35 | 3.05 | -8.27 | 3.76 | 75.94 | 76.13 | -13.47 | 7.69 | 0.9947 | 15.57 | 0.7709 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Regeneron Pharmaceuticals Inc | 13.10bn | 3.86bn | 114.21bn | 13.45k | 30.61 | 4.23 | 26.60 | 8.72 | 33.86 | 33.86 | 114.89 | 244.93 | 0.4067 | 0.6974 | 2.53 | 973,985.10 | 11.98 | 20.18 | 13.36 | 23.22 | 86.32 | 87.48 | 29.45 | 38.11 | 4.51 | -- | 0.091 | -- | 7.76 | 14.34 | -8.87 | 10.72 | 19.32 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Manulife Investment Management Ltd.as of 31 Dec 2023 | 365.71k | 0.06% |
| Amundi Asset Management US, Inc.as of 30 Apr 2024 | 108.53k | 0.02% |
| Henry James International Management, Inc.as of 31 Mar 2024 | 70.21k | 0.01% |
| MAI Capital Management LLCas of 31 Mar 2024 | 26.20k | 0.00% |
| Domini Impact Investments LLCas of 31 Jan 2024 | 21.80k | 0.00% |
| Yousif Capital Management LLCas of 31 Mar 2024 | 11.09k | 0.00% |
| RhumbLine Advisers LPas of 31 Mar 2024 | 10.86k | 0.00% |
| Lazard Asset Management LLCas of 30 Apr 2024 | 6.44k | 0.00% |
| PNC Investments LLCas of 31 Mar 2024 | 790.00 | 0.00% |
| ShariaPortfolio, Inc.as of 06 Jun 2024 | 777.00 | 0.00% |
